Is Concordia Healthcare Corp. a Buy on Takeover Rumours?

Don’t buy Concordia Healthcare Corp. (TSX:CXR)(NASDAQ:CXRX) on buyout rumours. Buy it on the very bright future it has ahead of it.

| More on:
The Motley Fool

Investors of Concordia Healthcare Corp. (TSX:CXR)(NASDAQ:CXRX) got a little reprieve on Thursday when the stock spiked 25% on rumours that Blackstone Group LP (NYSE:BX) was considering taking the company over. While the stock is still nowhere near its +$100 price it was enjoying in mid 2015, any increase is appreciated.

Blackstone clearly sees a company that is undervalued and will provide solid returns. And this buyout makes sense. According to one analyst, Concordia fits the bill for private equity because it has significant cash flow, its products have high margins, and it is diversified across multiple products.

Naturally, investors are considering whether or not to acquire shares on these rumours. In my opinion, I don’t like gambling on rumours that may or may not come to fruition. There’s no denying that Concordia is appropriately priced for a takeover, but too many things can go wrong when takeovers are in discussion.

However, that doesn’t mean investors shouldn’t buy this stock with a long-term mentality because even after rising 25%, it is still incredibly underpriced.

At $41 a share, the stock is trading at a little over six times earnings. Even better, it is only trading at 4.2 times its forward earnings. The company expects its earnings to grow significantly and, if previous years reveal anything, future growth is lucrative.

In the third quarter, its adjusted earnings per share were US$1.46 on revenues of US$94.91. Compare that with the previous year’s adjusted EPS of US$0.56 on revenues of US$36.43. A big reason why the company was able to increase its earnings so significantly is because it integrated 18 products from Covis Pharma for $1.2 billion.

Guidance given by the company in February suggested that it would have earnings anywhere between US$6.29 and US$6.77.

On top of that, it also acquired Amdipharm Mercury Ltd. for US$3.5 billion, which should continue to help with earnings over the next few years. However, a big reason why I like this deal is because it gives Concordia access to over 100 countries. Presently, the bulk of Concordia’s earnings come from the United States; now it can sell its products in these other countries.

But let’s think about this from an analytical perspective…

With the stock trading at 6.1 times earnings, it is obviously very cheap. Assume that it was trading at 10 times its 2015 earnings and you see a price per share at $60. Grow that to 13 times 2015 earnings, and the stock trades at $85. It is easy to see why Blackstone wants to acquire Concordia. Even if it pays $50 a share, it’s still getting the stock for much cheaper than a very conservative 10 times multiple.

My recommendation is that investors should seriously consider acquiring shares of this company. While the takeover could limit the return on investment, I believe the future is very bright for this company. Even if the takeover doesn’t happen, you’ll be in a position to reap strong returns over the next few years. Acquiring shares now, even after a 25% increase in price, is still a smart move.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Jacob Donnelly has no position in any stocks mentioned.

More on Investing

tsx today
Stock Market

TSX Today: What to Watch for in Stocks on Wednesday, July 17

Trading just below the key psychological level of 23,000, the TSX Composite has been posting fresh record highs for four…

Read more »

A steel grain silo storage tank with solar panel in a yellow canola field in bloom in Alberta, Canada.
Dividend Stocks

Down by 26.77%: Now Might Be the Perfect Time to Buy Nutrien Stock

This TSX stock has seen share prices fall by over 26% from its 52-week highs, but it might be the…

Read more »

Woman has an idea
Dividend Stocks

2 No-Brainer Stocks to Buy Now With $7,000

Two relatively cheap cash cows are no-brainer buys for investors with $7,000 to invest.

Read more »

dividends grow over time
Dividend Stocks

Buy This High-Yield Dividend Stock in July 2024

Buy this high-yielding dividend stock to lock in inflated yield into your portfolio to generate solid passive income for years.

Read more »

Double exposure of a businessman and stairs - Business Success Concept
Dividend Stocks

Where Will Dollarama Stock Be in 3 Years?

Dollarama stock has done incredibly well during economic uncertainty, but what about when the markets recover in the next three…

Read more »

edit Woman calculating figures next to a laptop
Tech Stocks

How to Buy UiPath Stock in Canada

UiPath is a beaten-down AI stock that trades at a massive discount to its earnings growth. Is the tech stock…

Read more »

Piggy bank with word TFSA for tax-free savings accounts.
Dividend Stocks

TFSA – 2 Canadian Stocks to Buy and Hold for Tax-Free Gains

Canadian stocks like Brookfield Corp (TSX:BN) can make wise TFSA holdings.

Read more »

Doctor talking to a patient in the corridor of a hospital.
Dividend Stocks

3 Things You Need to Know if You Buy NorthWest REIT Today

This REIT holds a super high dividend yield at 7.2%, but before you invest here is exactly what investors need…

Read more »